IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
IMUNON (NASDAQ: IMNN) presented promising new translational data from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study, involving 112 participants, demonstrated significant improvements in the tumor micro-environment (TME) through the local administration of IL-12 immunotherapy.
Key findings showed a positive TME shift in the majority of participants, with 50-80% of samples showing increased anti-tumor cells and 65-80% showing decreased immunosuppressive markers. The therapy effectively transformed "cold" tumors to "hot" by activating both innate and adaptive immune systems, while maintaining a favorable safety profile.
The company has initiated its pivotal Phase 3 OVATION 3 Study with four active trial sites currently enrolling patients.
IMUNON (NASDAQ: IMNN) ha presentato nuovi dati traslazionali promettenti dal suo studio di fase 2 OVATION 2 su IMNN-001, una immunoterapia mediata da DNA per il cancro ovarico avanzato. Lo studio, che ha coinvolto 112 partecipanti, ha mostrato miglioramenti significativi nell'ambiente tumorale (TME) mediante l'amministrazione locale dell'immunoterapia con IL-12. I risultati chiave hanno evidenziato uno spostamento positivo del TME nella maggior parte dei partecipanti, con 50-80% dei campioni che hanno mostrato un aumento delle cellule anti-tumore e 65-80% che hanno mostrato una diminuzione dei marker immunosoppressivi. La terapia ha efficacemente trasformato i tumori “freddi” in tumori “caldi” attivando sia i sistemi immunitari innati che quelli adattativi, mantenendo un profilo di sicurezza favorevole. L'azienda ha avviato il suo studio pivotante di fase 3 OVATION 3, con quattro centri di prova attualmente in reclutamento di pazienti.
IMUNON (NASDAQ: IMNN) presentó nuevos datos traslacionales prometedores de su Estudio OVATION 2 de Fase 2 sobre IMNN-001, una inmunoterapia mediada por ADN para el cáncer de ovario avanzado. El estudio, que involucró a 112 participantes, mostró mejoras significativas en el entorno tumoral (TME) mediante la administración local de la inmunoterapia con IL-12. Los hallazgos clave indicaron un cambio positivo en el TME en la mayoría de los participantes, con un 50-80% de las muestras mostrando un aumento de células anti-tumorales y un 65-80% mostrando una disminución de marcadores inmunosupresores. La terapia transformó eficazmente tumores “fríos” en tumores “calientes” al activar tanto los sistemas inmunitarios innato como adaptativo, manteniendo un perfil de seguridad favorable. La empresa ha iniciado su estudio pivotal de Fase 3 OVATION 3 con cuatro centros de ensayo activos que actualmente reclutan pacientes.
IMUNON (NASDAQ: IMNN)은 IMNN-001에 대한 2상 OVATION 2 연구의 유망한 새로운 번역적 데이터를 발표했습니다. DNA를 매개로 한 면역요법으로 진행된 이 치료는 진행성 난소암에 적용됩니다. 이 연구는 112명 참가자를 포함하며, IL-12 면역요법의 국소 투여를 통해 종양 미세환경(TME)의 현저한 개선을 보였습니다. 주요 결과는 다수의 참가자에서 TME가 긍정적으로 전환되었음을 시사하며, 샘플의 50-80%가 항종양 세포의 증가를, 65-80%가 면역억제 마커의 감소를 보였습니다. 이 요법은 고립된 종양을 ‘핫’으로 전환시켜 선천적 및 적응면역 시스템을 모두 활성화하는 동시에 양호한 안전성 프로파일을 유지했습니다. 회사는 현재 환자 모집 중인 네 군데의 활성 시험 사이트와 함께 Phase 3 OVATION 3 연구를 시작했습니다.
IMUNON (NASDAQ: IMNN) a présenté de prometteurs nouveaux données translationnelles de son étude de phase 2 OVATION 2 sur IMNN-001, une immunothérapie médiée par l’ADN pour le cancer ovarien avancé. L’étude, impliquant 112 participants, a montré des améliorations significatives de l’environnement tumoral (TME) grâce à l’administration locale de l’immunothérapie IL-12. Les résultats clés ont montré un déplacement positif du TME chez la majorité des participants, avec 50-80% des échantillons montrant une augmentation des cellules anti-tumorales et 65-80% montrant une diminution des marqueurs immunosuppresseurs. La thérapie a efficacement transformé les tumeurs « froides » en tumeurs « chaudes » en activant à la fois les systèmes immunitaires inné et adaptatif, tout en maintenant un profil de sécurité favorable. La société a lancé son étude pivot de Phase 3 OVATION 3 avec quatre sites d’essai actifs en cours d’inclusion de patients.
IMUNON (NASDAQ: IMNN) präsentierte vielversprechende neue translational Daten aus seiner Phase-2-OVATION-2-Studie zu IMNN-001, einer DNA-vermittelten Immuntherapie bei fortgeschrittenem Eierstockkrebs. Die Studie, an der 112 Teilnehmer beteiligt waren, zeigte signifikante Verbesserungen der Tumorumgebung (TME) durch die lokale Verabreichung der IL-12-Immuntherapie. Wichtige Ergebnisse zeigten eine positive TME-Verschiebung bei der Mehrzahl der Teilnehmer, wobei 50-80% der Proben eine Zunahme anti-tumoraler Zellen und 65-80% eine Abnahme immunosuppressiver Marker zeigten. Die Therapie hat effektiv kalte Tumore in heiße umgewandelt, indem sie sowohl angeborene als auch adaptive Immunsysteme aktiviert, bei gleichzeitig günstigem Sicherheitsprofil. Das Unternehmen hat seine entscheidende Phase-3-Studie OVATION 3 mit vier aktiven Standorten bereits gestartet, die derzeit Patienten rekrutieren.
IMUNON (NASDAQ: IMNN) قدمت بيانات ترجمة واعدة من تجربتها من المرحلة الثانية OVATION 2 حول IMNN-001، وهو علاج مناعي يعتمد على الحمض النووي لسرطان المبيض المتقدم. شملت الدراسة 112 مشاركاً، وأظهرت تحسناً كبيراً في بيئة الورم المحليّة (TME) من خلال الإدارة الموضعية للعلاج المناعي IL-12. أظهرت النتائج الرئيسية تحولاً إيجابياً في TME لمعظم المشاركين، مع أن 50-80% من العينات أظهرت زيادة في الخلايا المضادة للورم و 65-80% أظهرت انخفاضاً في علامات مثبطة للمناعة. حولت العلاج الأورام “الباردة” إلى “الحارة” بنشاط أنظمة المناعة الفطرية والتكيفية مع الحفاظ على ملف أمان مفضل. بدأت الشركة دراستها الحاسمة من المرحلة 3 OVATION 3 مع وجود أربعة مواقع تجربة حالياً في التجنيد.
IMUNON (NASDAQ: IMNN) 公布了来自其二期OVATION 2研究的有前景的新转化数据，针对IMNN-001，这是一种DNA介导的免疫治疗，用于晚期卵巢癌。该研究共涉及112名参与者，通过IL-12免疫治疗的局部给药，在肿瘤微环境（TME）方面显示出显著改善。关键发现显示大多数参与者的TME发生了积极改变，样本的50-80%显示抗肿瘤细胞增加，65-80%显示免疫抑制标志物降低。这种疗法通过激活固有和适应性免疫系统，将“冷”肿瘤转变为“热”肿瘤，同时保持有利的安全性概况。公司已启动其阶段3关键试验OVATION 3，现有四个活跃试验点正在招募患者。
- Positive shift in tumor micro-environment (TME) observed in majority of participants
- Significant increase in anti-tumor cells in 50-80% of paired samples
- Decrease in immunosuppressive markers in 65-80% of samples
- Favorable safety profile maintained throughout the study
- Successfully initiated Phase 3 OVATION 3 trial with four active sites
- None.
Insights
IMUNON's IMNN-001 shows promising 13-month survival extension in ovarian cancer with favorable immune system changes and Phase 3 trial underway.
The translational data presented for IMNN-001 represents a significant development in ovarian cancer treatment. The 13-month overall survival extension is particularly noteworthy as survival improvements of this magnitude are rare in advanced ovarian cancer, where progress has been incremental over decades.
What makes these results mechanistically compelling is the demonstrated conversion of "cold" tumors to "hot" ones. The data shows IMNN-001 effectively remodels the tumor microenvironment by increasing CD8+ T cells (the critical cancer-killing cells) while simultaneously reducing immunosuppressive elements like regulatory T cells, IDO+ and PDL1+ cells. This favorable shift occurred in 50-80% of patient samples, indicating robust biological activity.
The IL-12 approach is particularly elegant because it activates both innate and adaptive immune responses. Unlike many immunotherapies that target single pathways, IL-12 orchestrates a comprehensive immune response. The intraperitoneal administration method is also strategically sound for ovarian cancer, which primarily spreads within the peritoneal cavity, allowing targeted delivery with minimal systemic toxicity.
The advancement to Phase 3 is the logical next step after these promising results. With four sites currently enrolling patients, IMUNON appears on track, though expansion to additional sites will be crucial for timely completion of this pivotal trial. The company is now transitioning from proof-of-concept to potential registration, representing a critical inflection point in IMNN-001's development journey.
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment
Pivotal Phase 3 trial of IMNN-001 underway, with four trial sites activated to date and on plan for site expansion to accelerate patient recruitment
LAWRENCEVILLE, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced the presentation of new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational gene-based interleukin-12 (IL-12) immunotherapy based on the Company’s proprietary TheraPlas® technology platform, for the treatment of newly diagnosed advanced ovarian cancer. Results were highlighted in a presentation at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research held in Denver, Colorado.
The Phase 2 OVATION 2 Study assessed 112 participants treated with IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus standard-of-care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT). IMUNON reviewed translational data on the changes induced by the local administration of IL-12 and its downstream effectors in the tumor micro-environment (TME) from paired samples (pre- and post-treatment) from study participants. Results presented at the AACR Special Conference demonstrated:
- Positive shift in the local TME to favorable immune stimulatory T cell ratios in the majority of participants treated with IMNN-001, including favorable ratios of CD8+/T regulatory (Treg) cells, CD8+/IDO+ cells, and CD8+/CD4+ cells.
- TME shift in favor of decreased immunosuppression cells (IDO+, PDL1+, Treg, CD4+) and increased immunostimulatory cells (CD8+, CD8+ effector, myeloid dendritic cells) in the majority of participants post-treatment.
- IMNN-001 treatment creates a “hot” anti-TME by increasing the recruitment of anti-tumor CD8+ and myeloid dendritic cells in 50
-80% of the paired samples and decreasing immunosuppressive markers (IDO, PDL1, Treg cells) in 65-80% of the samples. - IMNN-001 continues to show a favorable safety profile.
“These new translational data are very encouraging and strongly reinforce and are consistent with the unprecedented positive overall survival results previously reported from the OVATION 2 Study,” said Douglas V. Faller, M.D., Ph.D., Chief Medical Officer of IMUNON and study presenter at the AACR conference. “Results from the study continue to validate our TheraPlas® technology and the broad impact of IMNN-001 on important cancer-fighting cytokines, effectively turning the tumor microenvironment from “cold” to ‘hot’ by activating both innate and adaptive immune systems, with limited to no systemic toxicities. IMNN-001 has shown significant therapeutic potential in clinical trials thus far, and the robust survival benefits and favorable safety profile observed align with these translational findings, supporting our ongoing Phase 3 OVATION 3 trial. We look forward to advancing the Phase 3 trial as quickly as possible for the many women with advanced ovarian cancer who are in urgent need of new, innovative treatment options.”
The OVATION 2 Study poster presentation is available on the “Scientific Presentations” page of IMUNON’s website at https://investors.imunon.com/scientific-presentations.
In July 2025, the Company announced treatment of the first patient in the pivotal Phase 3 OVATION 3 Study and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have been activated to date and are open for patient enrollment.
About the OVATION 3 Study
OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced epithelial ovarian cancer. The study is supported with unprecedented overall survival (OS) data from a large, 112-patient, randomized Phase 2 study showing the following:
- Median 13-month increase in OS (HR 0.70) and median 3-month increase in PFS (HR 0.79) in IMNN-001 treatment arm compared to standard of care alone.
- Better therapeutic effect observed with IMNN-001 treatment compared to the control arm (p=0.0375), as shown by mean 6.5-month extension of time free of progression or death (PFS + OS) captured in totality of treatment effect.
- Use of poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy further enhanced outcomes, with median OS not yet reached in the IMNN-001 treatment arm as patients surpass >5 years since randomization in the trial compared to 37 months on standard of care (HR 0.42).
The results from the OVATION 2 Study have resulted in invitations to present data from the Phase 2 Study at both the ASCO and ESMO annual meetings and in the peer-reviewed journal Gynecologic Oncology.
OVATION 3 is currently enrolling patients at four trial sites with up to 46 additional sites being considered for activation.
About the Phase 2 OVATION 2 Study
OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following N/ACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized 1:1 and evaluated for safety and efficacy to compare N/ACT plus IMNN-001 versus standard-of-care N/ACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m2 in addition to N/ACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate, chemotherapy response score and surgical response score.
About IMNN-001 Immunotherapy
Designed using IMUNON's proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.
About Epithelial Ovarian Cancer
Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
What are the key findings from IMUNON's Phase 2 OVATION 2 Study for IMNN-001?
How many participants were involved in IMUNON's Phase 2 OVATION 2 Study?
What is the current status of IMUNON's Phase 3 OVATION 3 trial?
How is IMNN-001 administered to ovarian cancer patients?
What type of therapy is IMUNON's IMNN-001?
